• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Finance

Finance

Ferring And Pharmabiome Enter into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement

December 11, 2023 Microbiome Times

Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research & development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. The deal provides Ferring with exclusive rights to […]

Finance

L’Oréal acquires research firm Lactobio

December 6, 2023 Microbiome Times

L’Oréal announced that it has completed the acquisition of Lactobio, a leading probiotic and microbiome research company based in Copenhagen. The strategic acquisition builds on 20 years of advanced research by L’Oréal into the microbiome scientific […]

Finance

Eligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic Medicines

December 5, 2023 Microbiome Times

Paris, FRANCE – December 5 2023 – Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful $30 million Series B […]

Finance

Vedanta Biosciences’ Key Microbiome Patents Fully Upheld in Three European Opposition Proceedings

November 29, 2023 Microbiome Times

Vedanta Biosciences, a clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the Opposition Division of the European Patent Office (EPO) has fully upheld Vedanta’s foundational […]

Finance

Boehringer Ingelheim acquires bacterial cancer therapy specialist T3 Pharma

November 22, 2023 Microbiome Times

Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF. T3 Pharma has developed a proprietary therapy […]

Finance

Synlogic reports Q3 results, including underwritten public offering of $21.0M and $2.5M milestone payment from Roche

November 11, 2023 Microbiome Times

Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today reported financial results for the third quarter ended September 30, 2023, and provided […]

Finance

Seres Therapeutics announces strategic restructuring and third quarter financial results including VOWST™ net sales

November 6, 2023 Microbiome Times

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, reported on November 2nd financial results for the third quarter ended September 30, 2023, including VOWST net sales of $7.6 million. Third quarter VOWST commercial […]

Finance

Fonterra and APC Microbiome Ireland have announce the establishment of a new microbiome research centre

October 27, 2023 Microbiome Times

Senior Fonterra Managers Dr Mark Malone and Dr Shalome Bassett were in Ireland to launch the ‘Fonterra Microbiome Research Centre (Ireland)’, their new collaboration with APC Microbiome Ireland (APC), a world renowned SFI Research Centre […]

Finance

Lallemand Health Solutions is strengthening its strategic position in the microbiome field through CDMO operations

October 20, 2023 Microbiome Times

Lallemand Health Solutions is strengthening its strategic position in the microbiome field through contract development and manufacturing operations, with the launch of Expert’Biome™ CDMO by Lallemand. With Expert’Biome™, Lallemand Health Solutions aims to support partners […]

Finance

Kanvas Biosciences Acquires Federation Bio Assets to Scale Discovery, Development and Manufacturing

October 12, 2023 Microbiome Times

Kanvas Biosciences, announced it acquired two active therapeutics programs, a microbial library, and intellectual property from Federation Bio, a manufacturer of live biotherapeutics products (LBPs). This acquisition transitions Kanvas Biosciences from a technology company with […]

Finance

Clinical Microbiomics announces merger with CosmosID

October 11, 2023 Microbiome Times

Clinical Microbiomics A/S, a leading innovator in bioinformatics and systems biology for the microbiome field based in Copenhagen, Denmark, announces the merger with CosmosID Inc, a leading CLIA-certified, GxP-compliant microbiome CRO based in Germantown, Maryland, United States. Clinical Microbiomics and […]

Posts navigation

« 1 … 5 6 7 … 32 »

Sign Up to Free Newsletter

QIAGEN WEBINAR SERIES – REGISTER HERE

NEW WHITEPAPER: ORAL DELIVERY OF LIVE BIOTHERAPEUTIC PRODUCTS:

Editor’s Choice

  • LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vaginosis
    May 1, 2026
  • Lactic Acid’s Untapped Potential to Optimise the Vaginal Microbiota and Mucosal Environment
    April 8, 2026
  • Multi-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence
    March 24, 2026
  • Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
    February 11, 2026
  • Immunity as a Lifestyle Priority
    January 30, 2026
sign up

Sign up to the Microbiome Times newsletter